Kenneth T. Jones files SEC Form 4 disclosures for Zynerba Pharmaceuticals, Inc.. They have made 1 open-market trade across 1 company since 2023, most recently 2023-10-10.
CIK 0001988882
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ZYNE | 45,000 | $59K |
Shares reported on the most recent Form 4, priced at the 2023-10-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ZYNE | SELL | 2023-09-13 | 2023-09-14 | $1.33 | $3K | -3.8% | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.